Anti-viral activity of thiazole derivatives: an updated patent review

ABSTRACT

Introduction

Several viral infections cause life-threatening consequences in humans, making them the most serious public health concerns. Despite the fact that several antiviral medicines are available on the market, there is no full treatment for many important viral infections. To date, antiviral medicines have significantly reduced the spread of epidemics, but their continued use has resulted in the creation of drug-resistant variants throughout time. As a result, the development of new, safe, and efficient antiviral drugs is critical

Areas covered

This review covered reports in the patent literature in the period 2014 to the first quarter of 2021 on the antiviral activities of thiazole derivatives. These molecules were reported to inhibit a wide range of viruses including influenza viruses, coronaviruses, herpes viruses, hepatitis B and C, bovine viral diarrhea virus, chikungunya virus and human immunodeficiency viruses.

Expert opinion

The most bioactive molecules can be used as lead structures for the development of new thiazole compounds with potent and selective antiviral activity. In addition, more efforts are needed to better understand the host-virus interactions for the discovery and development of new therapeutic agents and creative treatment strategies that are supposed to improve rates of clinical cure of the serious viruses.

KEYWORDS:

• thiazoles
• anti-viral
• biological activity
• anti-HBV
• anti-HCV

Article highlights

• This review covered reports in the patent literature in the period 2014 to the first quarter of 2021 on the antiviral activities of thiazole molecules.

• Large number of patents were showed that the thiazole derivatives have good anti-HBV activity.

• Thiazole derivatives play a vital role in fighting influenza viruses as H1N1 and H3N2.

• Thiazoles well known with their ablity to inhibit the HCV and HIV

• The thiazole-bearing drug nitazoxanide is presently in late clinical phase 3 for the treatment of COVID-19.

Declaration of interests

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.